MERTK and myeloid sarcoma: Compared with untreated mature DCs, trials of therapy with autologous tolDCs treated with dexamethasone and loaded with seven peptides derived from myelin (MBP13-32, MBP83-99, MBP11-129, MBP146-170, MOG1-20, MOG35-55, and PLP139-154) in MS patients (progressive course) revealed increased expression of the MERTK protein, a marker of tolDCs.